The PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,029
- 试验地点
- 3
- 主要终点
- Assess change in weight from baseline to 52 weeks
研究概览
简要总结
This is a multisite clinical trial of healthy lifestyle programs for middle-to-older-aged adults (50 -74 years) to improve their weight and, therefore, reduce risk for chronic disease. This study will investigate whether a proven, self-directed video-based lifestyle program can be significantly enhanced with the assistance of a coach via videoconference or phone to help people as they adopt healthy eating and exercise behaviors. Additionally, the study will examine what factors might explain why some people achieve better outcomes than others. Understanding this can help to tailor the program to an individual for personalized care in the future.
Importantly, this study aims to demonstrate how readily a digital lifestyle program, with or without remote coaching, can be seamlessly delivered to patients at home via the patient portal of their electronic health record. This practical use of existing telehealth tools could be a feasible and effective means to offer behavioral treatments during routine medical care.
详细描述
This multisite clinical trial uses a 2-stage sequential randomization design to test the adaptive and nonadaptive augmentation of a validated Group Lifestyle Balance (GLB) video program (base intervention) using problem solving treatment (PST), a proven behavior therapy. The GLB video program will be delivered via the patient portal of the electronic health record system. Trained coaches will deliver PST remotely via videoconference or phone.
English-speaking adults (N=1029), 50-74 years of age with a body mass index ≥27 and ≥1 cardiometabolic conditions, will be randomized at baseline to base intervention or waitlist control. Participants initially randomized to the waitlist control will be re-randomized after a 12-week control period to receive the base (Group A) or the augmented intervention (Group B), without tailoring based on early weight loss. Among participants initially randomized to the base intervention, responders defined by ≥3% weight loss at 6 weeks will continue the base intervention (Group C); nonresponders who are participants with <3% weight loss or missing weight data by 6 weeks will be re-randomized to continue the base intervention alone (Group D) or augmented with PST coaching via videoconference (Group E).
The investigators hypothesize: (1) the augmented intervention will be more effective than the base intervention both among early nonresponders to the base intervention (adaptive) and among participants in the waitlist control condition (nonadaptive) at 52 weeks; (2) the adaptive augmented intervention will be more efficacious than the base intervention and more efficacious than the waitlist control condition at 12 weeks. Aim 2 is to identify predictors of clinically significant (5%) weight loss for individual patients, using sociodemographic, clinical and behavioral engagement characteristics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Double (Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 50 - 74 years (inclusive)
- •Confirmed body mass index (BMI) ≥27.0 based on:
- •Weight measured by participant at home using the study-provided wireless weight scale
- •Height documented in the EHR during at least 2 separate ambulatory care encounters within the past 2 years
- •Diagnosis of 1 or more cardiometabolic condition (prediabetes, metabolic syndrome, type 2 diabetes, hypertension, dyslipidemia) in the EHR
- •Willing and able to accept randomization, and provide written informed consent and HIPAA authorization
- •Willing and able to participate in all aspects of the data collection and intervention protocols, including remote monitoring with a study-provided wireless weight scale and activity tracker and the use of a study tablet for access of MyChart, REDCap, and Fitbit apps
排除标准
- •Unable to speak, read, understand English sufficiently for informed consent
- •No reliable Wi-Fi Internet access at home
- •Self-report of current active weight loss treatment, including research-based commercial weight loss programs (e.g., Weight Watchers, Jenny Craig, HMR, Omada, TOPS), other weight loss or related behavioral health or wellness programs led by trained personnel (professional or lay) at the recruiting clinic or in the local community, and prescription weight loss medications
- •Screen positive for active eating disorder (bulimia nervosa or binge eating disorder) using PHQ- eating disorder module
- •Planned or prior bariatric surgery within the last 2 years (Note: patients who are more than 2 years post bariatric surgery can participate if otherwise eligible)
- •Unable to pass the Revised Physical Activity Readiness Questionnaire (PAR-Q) or obtain physician medical clearance to participate
- •Presence of any significant safety concerns or contraindications related to serious physical or mental health issues based on the EHR or self-report (e.g., type 1 diabetes or insulin dependence, myocardial infarction, stroke, cancer diagnosis (other than non-melanoma skin cancer) within the past 12 months and/or actively receiving cancer treatment, end-stage organ failure, bipolar disorder, psychosis, life expectancy <12 months)
- •Cognitive impairment based on the Callahan 6-item screener
- •Active alcohol or substance use disorder (including prescription drugs) based on the CAGE Questionnaire Adapted to Include Drugs (CAGE-AID)
- •Discontinued health care at the recruiting site, or plan to discontinue in the next 12 months
- •Participation in other behavioral, medical or surgical treatment studies by self-report that conflict with the primary weight loss outcome of this study.
- •Family/household member of an already enrolled participant or of a study team member
- •Investigator discretion for clinical safety or protocol adherence reasons
研究组 & 干预措施
Group B: Waitlist-Augmented Intervention
Participants in Group B will be in the waitlist control condition initially and transition to receive the augmented intervention at Week 12, which includes 12 GLB video sessions plus one-on-one PST from Week 13-24 and digital messages plus group-based PST from Week 25-52. Trained coaches will deliver the PST via videoconference (preferred) or phone.
干预措施: Augmented Intervention (Behavioral)
Group C: Base Intervention (Responders)
Participants in Group C will be the individuals initially randomized to receive the base intervention who achieve 3% weight loss or more by Week 6 after completing the first 6 GLB videos. They will continue the base intervention without re-randomization and complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52.
干预措施: Base intervention (Behavioral)
Group A: Waitlist-Base Intervention
Participants in Group A will be in the waitlist control condition initially and transition to receive the base intervention at Week 12, which includes 12 GLB video sessions from Week 13-24 and digital messages from Week 25-52.
干预措施: Base intervention (Behavioral)
Group D: Base Intervention (Non-responders)
Participants in Group D will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to continue the base intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52.
干预措施: Base intervention (Behavioral)
Group E: Augmented Intervention (Non-responders)
Participants in Group E will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to receive the augmented intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52. They will also work with a trained coach via videoconference (preferred) or phone to receive one-on-one PST from Week 7-24 and group-based PST from Week 25-52.
干预措施: Augmented Intervention (Behavioral)
结局指标
主要结局
Assess change in weight from baseline to 52 weeks
时间窗: Baseline, 52 weeks
All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). At baseline (0) and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to weigh themselves at the same time on at least 3 days during the week. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible). They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.
次要结局
- Assess changes in fruit/veggie/fat/fiber intake at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess changes in problem solving ability at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess changes in cardiovascular risk at 52 weeks(Baseline, 52 weeks)
- Assess changes in number/severity of comorbidity at 52 weeks(Baseline, 52 weeks)
- Assess changes in efficacy in diet change at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess changes in sleep disturbance score at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess changes in cognitive functioning at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess changes in sleep impairment score at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess changes in efficacy in weight control at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess changes in efficacy in physical activity at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess changes in health-related quality of life at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess changes in physical activity using the International Physical Activity Questionnaire at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess changes in patient activation at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess changes in perceived stress at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess changes in social support/autonomous support per Health Care Climate Questionnaire at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess changes in number of steps using Fitbit activity tracker at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- Assess trajectories of weight change from baseline to 6, 12, 24, and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks)
- Assess changes in sleep metrics using Fitbit activity tracker at 6, 12, 24 and 52 weeks(Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks)
- GLB videos viewed(Throughout the intervention, up to 1 year)
- PST coaching sessions completed(Throughout the intervention, up to 1 year)
- Self-monitoring of weight(Through study completion, an average of 1 year)
- Self-monitoring of activity & sleep(Through study completion, an average of 1 year)
- Assess change in weight from baseline to 12 weeks(Baseline, 12 weeks,)
研究者
Jun Ma
MD, PhD, Principal Investigator, Beth and George Vitoux Professor of Medicine
University of Illinois at Chicago